Geoffrey Alan Donnan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/633628/publications.pdf

Version: 2024-02-01

608 papers 61,550 citations

103 h-index 233

g-index

624 all docs

624 docs citations

times ranked

624

35124 citing authors

#	Article	IF	Citations
1	Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet, The, 2016, 387, 1723-1731.	6.3	5,331
2	Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection. New England Journal of Medicine, 2015, 372, 1009-1018.	13.9	4,778
3	Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet, The, 1998, 352, 1245-1251.	6.3	3,216
4	Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet, The, 2004, 363, 768-774.	6.3	2,316
5	Stroke. Lancet, The, 2008, 371, 1612-1623.	6.3	2,127
6	Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet, The, 2014, 384, 1929-1935.	6.3	1,971
7	Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, The, 2010, 375, 1695-1703.	6.3	1,871
8	Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis. JAMA - Journal of the American Medical Association, 2016, 316, 1279.	3.8	1,617
9	1,026 Experimental treatments in acute stroke. Annals of Neurology, 2006, 59, 467-477.	2.8	1,238
10	Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurology, The, 2008, 7, 299-309.	4.9	971
11	Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. New England Journal of Medicine, 2008, 359, 1238-1251.	13.9	882
12	Ischaemic stroke. Nature Reviews Disease Primers, 2019, 5, 70.	18.1	849
13	Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. New England Journal of Medicine, 2018, 379, 1509-1518.	13.9	770
14	Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. New England Journal of Medicine, 2008, 359, 1225-1237.	13.9	703
15	Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. New England Journal of Medicine, 2019, 380, 1795-1803.	13.9	653
16	Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. New England Journal of Medicine, 2018, 379, 1519-1528.	13.9	591
17	Activated Macrophages and Microglia Induce Dopaminergic Sprouting in the Injured Striatum and Express Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor. Journal of Neuroscience, 1999, 19, 1708-1716.	1.7	546
18	Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. New England Journal of Medicine, 2018, 378, 1573-1582.	13.9	538

#	Article	IF	Citations
19	A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke. New England Journal of Medicine, 2012, 366, 1099-1107.	13.9	530
20	Inactive and Alone. Stroke, 2004, 35, 1005-1009.	1.0	524
21	Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias. Stroke, 2004, 35, 1203-1208.	1.0	522
22	One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. New England Journal of Medicine, 2016, 374, 1533-1542.	13.9	444
23	Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain, 2007, 130, 3063-3074.	3.7	413
24	Effect of Aspirin on Disability-free Survival in the Healthy Elderly. New England Journal of Medicine, 2018, 379, 1499-1508.	13.9	392
25	Quality of Life After Stroke. Stroke, 2004, 35, 2340-2345.	1.0	381
26	Cerebral Blood Flow Is the Optimal CT Perfusion Parameter for Assessing Infarct Core. Stroke, 2011, 42, 3435-3440.	1.0	359
27	Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Annals of Neurology, 2002, 51, 28-37.	2.8	355
28	Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. New England Journal of Medicine, 2016, 374, 2313-2323.	13.9	352
29	Global stroke statistics. International Journal of Stroke, 2017, 12, 13-32.	2.9	351
30	Global Stroke Statistics. International Journal of Stroke, 2014, 9, 6-18.	2.9	329
31	A Very Early Rehabilitation Trial for Stroke (AVERT). Stroke, 2008, 39, 390-396.	1.0	328
32	Extending thrombolysis to 4·5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet, The, 2019, 394, 139-147.	6.3	321
33	Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurology, The. 2008, 7, 875-884.	4.9	310
34	Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurology, The, 2012, 11, 315-322.	4.9	310
35	Good Laboratory Practice. Stroke, 2009, 40, 221-3.	1.0	292
36	Streptokinase for Acute Ischemic Stroke With Relationship to Time of Administration. JAMA - Journal of the American Medical Association, 1996, 276, 961.	3.8	290

#	Article	lF	Citations
37	Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. Lancet Neurology, The, 2018, 17, 895-904.	4.9	281
38	Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke. Lancet Neurology, The, 2015, 14, 846-854.	4.9	280
39	Incidence of the Major Stroke Subtypes. Stroke, 2001, 32, 1732-1738.	1.0	279
40	Evidence for the Efficacy of NXY-059 in Experimental Focal Cerebral Ischaemia Is Confounded by Study Quality. Stroke, 2008, 39, 2824-2829.	1.0	279
41	Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data. Lancet Neurology, The, 2019, 18, 46-55.	4.9	276
42	Stroke Thrombolysis. Stroke, 2014, 45, 1053-1058.	1.0	270
43	Very Early Mobilization After Stroke Fast-Tracks Return to Walking. Stroke, 2011, 42, 153-158.	1.0	257
44	Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. New England Journal of Medicine, 2018, 378, 2182-2190.	13.9	238
45	RAPID Automated Patient Selection for Reperfusion Therapy. Stroke, 2011, 42, 1608-1614.	1.0	235
46	Failure of Collateral Blood Flow is Associated with Infarct Growth in Ischemic Stroke. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1168-1172.	2.4	235
47	Global Stroke Statistics 2019. International Journal of Stroke, 2020, 15, 819-838.	2.9	226
48	World Stroke Organization Global Stroke Services Guidelines and Action Plan. International Journal of Stroke, 2014, 9, 4-13.	2.9	223
49	Level of Systolic Blood Pressure Within the Normal Range and Risk of Recurrent Stroke. JAMA - Journal of the American Medical Association, 2011, 306, 2137-44.	3.8	215
50	Refining the Definition of the Malignant Profile. Stroke, 2011, 42, 1270-1275.	1.0	209
51	Safety and Efficacy of Solitaire Stent Thrombectomy. Stroke, 2016, 47, 798-806.	1.0	209
52	Effect of general anaesthesia on functional outcome in patients with anterior circulation ischaemic stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data. Lancet Neurology, The, 2018, 17, 47-53.	4.9	205
53	Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurology, The, 2009, 8, 261-269.	4.9	193
54	Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes. Stroke, 2016, 47, 2373-2379.	1.0	193

#	Article	IF	CITATIONS
55	Comparison of Computed Tomography Perfusion and Magnetic Resonance Imaging Perfusion-Diffusion Mismatch in Ischemic Stroke. Stroke, 2012, 43, 2648-2653.	1.0	192
56	Acute Stroke Imaging Research Roadmap II. Stroke, 2013, 44, 2628-2639.	1.0	192
57	Cost of Stroke in Australia From a Societal Perspective. Stroke, 2001, 32, 2409-2416.	1.0	191
58	Stroke Incidence on the East Coast of Australia. Stroke, 2000, 31, 2087-2092.	1.0	187
59	Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurology, The, 2016, 15, 925-933.	4.9	187
60	A Multicentre, Randomized, Double-Blinded, Placebo-Controlled Phase III Study to Investigate Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND). International Journal of Stroke, 2012, 7, 74-80.	2.9	182
61	Inflammation following stroke. Journal of Clinical Neuroscience, 2006, 13, 1-8.	0.8	181
62	Dementia, Stroke, and Vascular Risk Factors; a Review. International Journal of Stroke, 2012, 7, 61-73.	2.9	181
63	Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques. Stroke, 2014, 45, 1248-1257.	1.0	178
64	Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet, The, 2019, 393, 877-888.	6.3	178
65	Carotid endarterectomy for asymptomatic carotid stenosis. The Cochrane Library, 2005, , CD001923.	1.5	176
66	The Infarct Core is Well Represented by the Acute Diffusion Lesion: Sustained Reversal is Infrequent. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 50-56.	2.4	172
67	Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke. JAMA - Journal of the American Medical Association, 2020, 323, 1257.	3.8	168
68	Excessive Incidence of Stroke in Iran. Stroke, 2010, 41, e3-e10.	1.0	167
69	Systematic Review and Metaanalysis of the Efficacy of FK506 in Experimental Stroke. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 713-721.	2.4	164
70	Mismatch-Based Delayed Thrombolysis. Stroke, 2010, 41, e25-33.	1.0	154
71	Pretreatment Diffusion- and Perfusion-MR Lesion Volumes Have a Crucial Influence on Clinical Response to Stroke Thrombolysis. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 1214-1225.	2.4	151
72	A Multicenter, Randomized, Controlled Study to Investigate Extending the Time for Thrombolysis in Emergency Neurological Deficits with Intra-Arterial Therapy (EXTEND-IA). International Journal of Stroke, 2014, 9, 126-132.	2.9	151

#	Article	IF	CITATIONS
7 3	Handicap After Stroke: How Does It Relate to Disability, Perception of Recovery, and Stroke Subtype?. Stroke, 2002, 33, 762-768.	1.0	148
74	Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 1586-1593.	1.7	143
7 5	Three Important Subgroups of Hypertensive Persons at Greater Risk of Intracerebral Hemorrhage. Hypertension, 1998, 31, 1223-1229.	1.3	140
76	Embolic Signals And Prediction of Ipsilateral Stroke or Transient Ischemic Attack in Asymptomatic Carotid Stenosis. Stroke, 2005, 36, 1128-1133.	1.0	140
77	Postthrombolysis Blood Pressure Elevation Is Associated With Hemorrhagic Transformation. Stroke, 2010, 41, 72-77.	1.0	139
78	Interrater Reliability of the National Institutes of Health Stroke Scale: Rating by Neurologistsand N urses in a Community-Based Stroke Incidence Study. Cerebrovascular Diseases, 1999, 9, 323-327.	0.8	134
79	Association of Time From Stroke Onset to Groin Puncture With Quality of Reperfusion After Mechanical Thrombectomy. JAMA Neurology, 2019, 76, 405.	4.5	133
80	Fiblast (Trafermin) in Acute Stroke: Results of the European-Australian Phase II/III Safety and Efficacy Trial. Cerebrovascular Diseases, 2002, 14, 239-251.	0.8	131
81	Brain Edema Predicts Outcome After Nonlacunar Ischemic Stroke. Stroke, 2014, 45, 3643-3648.	1.0	130
82	Assessing Reperfusion and Recanalization as Markers of Clinical Outcomes After Intravenous Thrombolysis in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). Stroke, 2009, 40, 2872-2874.	1.0	129
83	How to make better use of thrombolytic therapy in acute ischemic stroke. Nature Reviews Neurology, 2011, 7, 400-409.	4.9	128
84	Risk Factors for Cerebral Hemorrhage in the Era of Well-Controlled Hypertension. Stroke, 1996, 27, 2020-2025.	1.0	128
85	Stroke Symptoms and the Decision to Call for an Ambulance. Stroke, 2007, 38, 361-366.	1.0	127
86	Endovascular therapy for ischemic stroke. Neurology, 2017, 88, 2123-2127.	1.5	124
87	Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy. Lancet Neurology, The, 2002, 1, 417-425.	4.9	123
88	Determinants of Handicap After Stroke. Stroke, 2004, 35, 715-720.	1.0	123
89	Long-Term Outcome in the North East Melbourne Stroke Incidence Study. Stroke, 2005, 36, 2082-2086.	1.0	123
90	Stroke: Working Toward a Prioritized World Agenda. Stroke, 2010, 41, 1084-1099.	1.0	122

#	Article	IF	CITATIONS
91	Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. Journal of Pineal Research, 2005, 38, 35-41.	3.4	121
92	Adverse effects of low-dose aspirin in a healthy elderly population. Clinical Pharmacology and Therapeutics, 1993, 54, 84-89.	2.3	120
93	Worse Stroke Outcome in Atrial Fibrillation is Explained by More Severe Hypoperfusion, Infarct Growth, and Hemorrhagic Transformation. International Journal of Stroke, 2015, 10, 534-540.	2.9	118
94	Perfusion computed tomography to assist decision making for stroke thrombolysis. Brain, 2015, 138, 1919-1931.	3.7	118
95	A Digital Map of Middle Cerebral Artery Infarcts Associated With Middle Cerebral Artery Trunk and Branch Occlusion. Stroke, 2005, 36, 986-991.	1.0	116
96	The Impact of Ambulance Practice on Acute Stroke Care. Stroke, 2007, 38, 2765-2770.	1.0	114
97	Protocol and Pilot Data for Establishing the Australian Stroke Clinical Registry. International Journal of Stroke, 2010, 5, 217-226.	2.9	114
98	Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial. Lancet, The, 2022, 400, 116-125.	6.3	114
99	Evidence that patent foramen ovale is not a risk factor for cerebral ischemia in the elderly. American Journal of Cardiology, 1994, 74, 596-599.	0.7	113
100	Pathophysiological Determinants of Worse Stroke Outcome in Atrial Fibrillation. Cerebrovascular Diseases, 2010, 30, 389-395.	0.8	110
101	Regional Very Low Cerebral Blood Volume Predicts Hemorrhagic Transformation Better Than Diffusion-Weighted Imaging Volume and Thresholded Apparent Diffusion Coefficient in Acute Ischemic Stroke. Stroke, 2010, 41, 82-88.	1.0	109
102	Increased Risk of Cognitive Impairment 3 Months After Mild to Moderate First-Ever Stroke. Stroke, 2003, 34, 1136-1143.	1.0	108
103	The Benefits of Intravenous Thrombolysis Relate to the Site of Baseline Arterial Occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). Stroke, 2010, 41, 295-299.	1.0	108
104	Atheroma of the aortic arch: an important and poorly recognised factor in the aetiology of stroke. Lancet Neurology, The, 2004, 3, 408-414.	4.9	107
105	Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data. Lancet, The, 2020, 396, 1574-1584.	6.3	107
106	Long-Term Cognitive Transitions, Rates of Cognitive Change, and Predictors of Incident Dementia in a Population-Based First-Ever Stroke Cohort. Stroke, 2006, 37, 2479-2483.	1.0	102
107	Multicenter Comparison of Processes of Care Between Stroke Units and Conventional Care Wards in Australia. Stroke, 2004, 35, 1035-1040.	1.0	101
108	The Virtual International Stroke Trials Archive. Stroke, 2007, 38, 1905-1910.	1.0	101

#	Article	IF	Citations
109	Imaging Selection in Ischemic Stroke: Feasibility of Automated CT-Perfusion Analysis. International Journal of Stroke, 2015, 10, 51-54.	2.9	100
110	Dietary factors and the risk of glioma in adults: Results of a case-control study in melbourne, Australia. International Journal of Cancer, 1994, 59, 357-362.	2.3	99
111	Spontaneous Reperfusion After Ischemic Stroke Is Associated With Improved Outcome. Stroke, 1998, 29, 2522-2528.	1.0	98
112	Factors Affecting the Apparent Efficacy and Safety of Tissue Plasminogen Activator in Thrombotic Occlusion Models of Stroke: Systematic Review and Meta-Analysis. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 1905-1913.	2.4	96
113	Poststroke Chronic Disease Management: Towards Improved Identification and Interventions for Poststroke Spasticity-Related Complications. International Journal of Stroke, 2011, 6, 42-46.	2.9	94
114	Association of follow-up infarct volume with functional outcome in acute ischemic stroke: a pooled analysis of seven randomized trials. Journal of NeuroInterventional Surgery, 2018, 10, 1137-1142.	2.0	93
115	Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Annals of Neurology, 1992, 32, 339-344.	2.8	90
116	EPITHET. Stroke, 2011, 42, 59-64.	1.0	90
117	Motor Impairment and Recovery in the Upper Limb After Stroke. Stroke, 2005, 36, 625-629.	1.0	89
118	Evolution of Brain Activation with Good and Poor Motor Recovery after Stroke. Neurorehabilitation and Neural Repair, 2006, 20, 24-41.	1.4	89
119	Stroke: Working toward a Prioritized World Agenda. International Journal of Stroke, 2010, 5, 238-256.	2.9	89
120	Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging. Current Opinion in Neurology, 2005, 18, 47-52.	1.8	88
121	The 2007 Feinberg Lecture. Stroke, 2008, 39, 242-242.	1.0	88
122	Acute Stroke Imaging Research Roadmap III Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials. Stroke, 2016, 47, 1389-1398.	1.0	88
123	Stroke and nonstroke brain attacks in children. Neurology, 2014, 82, 1434-1440.	1.5	87
124	THRIVE Score Predicts Ischemic Stroke Outcomes and Thrombolytic Hemorrhage Risk in VISTA. Stroke, 2013, 44, 3365-3369.	1.0	86
125	Distribution of catecholamine uptake sites in human brain as determined by quantitative [3H] mazindol autoradiography. Journal of Comparative Neurology, 1991, 304, 419-434.	0.9	85
126	Lifetime Cost of Stroke Subtypes in Australia. Stroke, 2003, 34, 2502-2507.	1.0	84

#	Article	IF	CITATIONS
127	Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2012, 366, 1914-1922.	13.9	84
128	CT perfusion improves diagnostic accuracy and confidence in acute ischaemic stroke. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 613-618.	0.9	84
129	Stroke Units, Tissue Plasminogen Activator, Aspirin and Neuroprotection: Which Stroke Intervention Could Provide the Greatest Community Benefit?. Cerebrovascular Diseases, 2005, 20, 239-244.	0.8	83
130	The Effects of Alteplase 3 to 6 Hours After Stroke in the EPITHET–DEFUSE Combined Dataset. Stroke, 2013, 44, 87-93.	1.0	82
131	Pilot Study of Intravenous Glyburide in Patients With a Large Ischemic Stroke. Stroke, 2014, 45, 281-283.	1.0	82
132	Rationale, Design, and Progress of the ENhanced Control of Hypertension ANd Thrombolysis Stroke Study (ENCHANTED) Trial: An International Multicenter 2 × 2 Quasi-Factorial Randomized Controlled Trial of Low- vs. Standard-Dose rt-PA and Early Intensive vs. Guideline-Recommended Blood Pressure Lowering in Patients with Acute Ischaemic Stroke Eligible for Thrombolysis Treatment. International Journal of Stroke, 2015, 10, 778-788.	2.9	82
133	Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection. International Journal of Stroke, 2019, 14, 483-490.	2.9	82
134	The resistance to ischemia of white and gray matter after stroke. Annals of Neurology, 2004, 56, 695-701.	2.8	81
135	Rapid Assessment of Perfusion–Diffusion Mismatch. Stroke, 2008, 39, 75-81.	1.0	81
136	Prediction of Poststroke Hemorrhagic Transformation Using Computed Tomography Perfusion. Stroke, 2013, 44, 3039-3043.	1.0	80
137	Brief Comprehensive Quality of Life Assessment After Stroke. Stroke, 2002, 33, 2888-2894.	1.0	77
138	Salvaging The Ischaemic Penumbra: More Than Just Reperfusion?. Clinical and Experimental Pharmacology and Physiology, 2002, 29, 1-10.	0.9	77
139	Mediation of the Relationship Between Endovascular Therapy and Functional Outcome by Follow-up Infarct Volume in Patients With Acute Ischemic Stroke. JAMA Neurology, 2019, 76, 194.	4.5	77
140	Association of adult glioma with medical conditions, family and reproductive history. International Journal of Cancer, 1997, 71, 203-207.	2.3	76
141	4.5 Hours. Stroke, 2009, 40, 2266-2267.	1.0	75
142	Development, Expansion, and Use of a Stroke Clinical Trials Resource for Novel Exploratory Analyses. International Journal of Stroke, 2012, 7, 133-138.	2.9	75
143	A Very Early Rehabilitation Trial (AVERT). International Journal of Stroke, 2006, 1, 169-171.	2.9	74
144	Pretreatment Blood–Brain Barrier Damage and Post-Treatment Intracranial Hemorrhage in Patients Receiving Intravenous Tissue-Type Plasminogen Activator. Stroke, 2014, 45, 2030-2035.	1.0	73

#	Article	IF	CITATIONS
145	Effect of Statin Use During Hospitalization for Intracerebral Hemorrhage on Mortality and Discharge Disposition. JAMA Neurology, 2014, 71, 1364.	4.5	72
146	Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Research, 1987, 402, 269-274.	1.1	71
147	Risk of Ischemic Stroke Among Users of the Oral Contraceptive Pill. Stroke, 2003, 34, 1575-1580.	1.0	71
148	Greater Incidence of Both Fatal and Nonfatal Strokes in Disadvantaged Areas. Stroke, 2006, 37, 877-882.	1.0	71
149	New Strategy to Reduce the Global Burden of Stroke. Stroke, 2015, 46, 1740-1747.	1.0	71
150	Advanced imaging improves prediction of hemorrhage after stroke thrombolysis. Annals of Neurology, 2013, 73, 510-519.	2.8	70
151	Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2020, 19, 980-987.	4.9	70
152	Feasibility of conducting a primary prevention trial of lowâ€dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Medical Journal of Australia, 2008, 189, 105-109.	0.8	69
153	European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND. International Journal of Stroke, 2016, 11, 260-267.	2.9	69
154	Volumetric and Spatial Accuracy of Computed Tomography Perfusion Estimated Ischemic Core Volume in Patients With Acute Ischemic Stroke. Stroke, 2018, 49, 2368-2375.	1.0	69
155	Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial. Lancet Neurology, The, 2022, 21, 520-527.	4.9	69
156	Preclinical Drug Evaluation for Combination Therapy in Acute Stroke Using Systematic Review, Meta-Analysis, and Subsequent Experimental Testing. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 962-975.	2.4	68
157	Differential Prognosis of Isolated Cortical Swelling and Hypoattenuation on CT in Acute Stroke. Stroke, 2007, 38, 941-947.	1.0	67
158	The validity of brief screening cognitive instruments in the diagnosis of cognitive impairment and dementia after first-ever stroke. International Psychogeriatrics, 2006, 18, 295-305.	0.6	65
159	Time Is Penumbra: Imaging, Selection and Outcome. Cerebrovascular Diseases, 2014, 38, 59-72.	0.8	63
160	Rationale for a Trial of Low-Dose Aspirin for the Primary Prevention of Major Adverse Cardiovascular Events and Vascular Dementia in the Elderly. Drugs and Aging, 2003, 20, 897-903.	1.3	62
161	The Existence and Evolution of Diffusion–Perfusion Mismatched Tissue in White and Gray Matter After Acute Stroke. Stroke, 2005, 36, 2132-2137.	1.0	62
162	Incidence of Stroke Subtypes in the North East Melbourne Stroke Incidence Study (NEMESIS): Differences between Men and Women. Neuroepidemiology, 2009, 32, 11-18.	1.1	62

#	Article	IF	CITATIONS
163	Reprint: Good Laboratory Practice: Preventing Introduction of Bias at the Bench. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 221-223.	2.4	62
164	The Spot Sign and Tranexamic Acid on Preventing ICH Growth – AUStralasia Trial (STOP-AUST): Protocol of a Phase II Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. International Journal of Stroke, 2014, 9, 519-524.	2.9	62
165	Carotid-Artery Stenting in Stroke Prevention. New England Journal of Medicine, 2010, 363, 80-82.	13.9	60
166	Prevalence and Significance of Impaired Microvascular Tissue Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow). Neurology, 2022, 98, .	1.5	60
167	Tenecteplase in ischemic stroke offers improved recanalization. Neurology, 2017, 89, 62-67.	1.5	59
168	Visual Assessment of Perfusion-Diffusion Mismatch Is Inadequate to Select Patients for Thrombolysis. Cerebrovascular Diseases, 2010, 29, 592-596.	0.8	58
169	Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): A multicenter, randomized, controlled study. International Journal of Stroke, 2018, 13, 328-334.	2.9	58
170	Melbourne Mobile Stroke Unit and Reperfusion Therapy. Stroke, 2020, 51, 922-930.	1.0	58
171	Acute Stroke Biomarkers: Are We There Yet?. Frontiers in Neurology, 2021, 12, 619721.	1.1	58
172	Quality of Acute Care and Long-Term Quality of Life and Survival. Stroke, 2017, 48, 1026-1032.	1.0	56
173	Structural MRI markers of brain aging early after ischemic stroke. Neurology, 2017, 89, 116-124.	1.5	55
174	Twenty-Year History of the Evolution of Stroke Thrombolysis With Intravenous Alteplase to Reduce Long-Term Disability. Stroke, 2015, 46, 2341-2346.	1.0	54
175	Assessing Response to Stroke Thrombolysis. Archives of Neurology, 2012, 69, 46.	4.9	53
176	Endovascular Thrombectomy for Ischemic Stroke Increases Disability-Free Survival, Quality of Life, and Life Expectancy and Reduces Cost. Frontiers in Neurology, 2017, 8, 657.	1.1	53
177	Comparison of recruitment strategies for a large-scale clinical trial in the elderly. Journal of Clinical Epidemiology, 1991, 44, 1105-1114.	2.4	52
178	Incidence and Outcome of Subtypes of Ischaemic Stroke: Initial Results from the North East Melbourne Stroke Incidence Study (NEMESIS). Cerebrovascular Diseases, 2003, 15, 133-139.	0.8	52
179	Is White Matter Involved in Patients Entered into Typical Trials of Neuroprotection?. Stroke, 2005, 36, 2742-2744.	1.0	52
180	Glucose Modifies the Effect of Endovascular Thrombectomy in Patients With Acute Stroke. Stroke, 2019, 50, 690-696.	1.0	52

#	Article	IF	Citations
181	Pre-Stroke CHADS ₂ and CHA ₂ -VASc Scores Are Useful in Stratifying Three-Month Outcomes in Patients with and without Atrial Fibrillation. Cerebrovascular Diseases, 2013, 36, 273-280.	0.8	49
182	An Improved Method for Simple, Assumption-Free Ordinal Analysis of the Modified Rankin Scale Using Generalized Odds Ratios. International Journal of Stroke, 2014, 9, 999-1005.	2.9	49
183	Recovery Potential After Acute Stroke. Frontiers in Neurology, 2015, 6, 238.	1.1	49
184	Imaging the ischaemic penumbra. Current Opinion in Neurology, 2004, 17, 61-67.	1.8	48
185	Proof-of-Principle Phase II MRI Studies in Stroke. Stroke, 2006, 37, 2521-2525.	1.0	48
186	Development of a new tool to correlate stroke outcome with infarct topography: A proof-of-concept study. Neurolmage, 2010, 49, 127-133.	2.1	48
187	Relationship Between Touch Impairment and Brain Activation After Lesions of Subcortical and Cortical Somatosensory Regions. Neurorehabilitation and Neural Repair, 2011, 25, 443-457.	1.4	48
188	Charting Cognitive and Volumetric Trajectories after Stroke: Protocol for the Cognition and Neocortical Volume after Stroke (CANVAS) Study. International Journal of Stroke, 2014, 9, 824-828.	2.9	48
189	Atrial Fibrillation With Left Atrial Spontaneous Contrast Detected by Transesophageal Echocardiography Is a Potent Risk Factor for Stroke. American Journal of Cardiology, 1996, 78, 425-429.	0.7	47
190	Source of Microembolic Signals in Patients With High-Grade Carotid Stenosis. Stroke, 2002, 33, 2014-2018.	1.0	46
191	The ASPECTS template is weighted in favor of the striatocapsular region. Neurolmage, 2006, 31, 477-481.	2.1	46
192	Patients With Transient Ischemic Attack or Minor Stroke Should Be Admitted to Hospital. Stroke, 2006, 37, 1137-1138.	1.0	46
193	White Matter Medullary Infarcts: Acute Subcortical Infarction in the Centrum ovale. Cerebrovascular Diseases, 1998, 8, 289-295.	0.8	44
194	Evaluation of Combination Therapy in Animal Models of Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 585-597.	2.4	44
195	Validating Imaging Biomarkers of Cerebral Edema in Patients With Severe Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, 742-749.	0.7	44
196	The aspirin in reducing events in the elderly trial: Statistical analysis plan. International Journal of Stroke, 2018, 13, 335-338.	2.9	44
197	Expression of glial cell line-derived neurotrophic factor (GDNF) mRNA following mechanical injury to mouse striatum. NeuroReport, 1997, 8, 3097-3101.	0.6	43
198	Imaging the Ischemic Penumbra with 18 F-Fluoromisonidazole in a Rat Model of Ischemic Stroke. Stroke, 2004, 35, 975-980.	1.0	43

#	Article	IF	CITATIONS
199	Basilar Artery Thrombosis. Stroke, 2006, 37, 2440-2440.	1.0	43
200	Patterns of Stroke Recurrence According to Subtype of First Stroke Event: The North East Melbourne Stroke Incidence Study (NEMESIS). International Journal of Stroke, 2008, 3, 158-164.	2.9	43
201	An Early Mobilization Protocol Successfully Delivers More and Earlier Therapy to Acute Stroke Patients. Neurorehabilitation and Neural Repair, 2012, 26, 20-26.	1.4	43
202	Reperfusion after ischemic stroke is associated with reduced brain edema. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1807-1817.	2.4	43
203	Clinical–Diffusion Mismatch and Benefit From Thrombolysis 3 to 6 Hours After Acute Stroke. Stroke, 2009, 40, 2572-2574.	1.0	42
204	Intracerebral haemorrhage: a need for more data and new research directions. Lancet Neurology, The, 2010, 9, 133-134.	4.9	42
205	Differentiating Childhood Stroke From Mimics in the Emergency Department. Stroke, 2016, 47, 2476-2481.	1.0	42
206	Global stroke statistics: An update of mortality data from countries using a broad code of "cerebrovascular diseases― International Journal of Stroke, 2017, 12, 796-801.	2.9	42
207	Microvascular Dysfunction in Blood-Brain Barrier Disruption and Hypoperfusion Within the Infarct Posttreatment Are Associated With Cerebral Edema. Stroke, 2022, 53, 1597-1605.	1.0	42
208	Economic Evaluation of Australian Stroke Services. Stroke, 2006, 37, 2790-2795.	1.0	41
209	Exploratory Analysis of Glyburide as a Novel Therapy for Preventing Brain Swelling. Neurocritical Care, 2014, 21, 43-51.	1.2	41
210	STROKOG (stroke and cognition consortium): An international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 11-23.	1.2	41
211	Nimodipine and Perfusion Changes After Stroke. Stroke, 1999, 30, 1417-1423.	1.0	40
212	Breaking the 3 h barrier for treatment of acute ischaemic stroke. Lancet Neurology, The, 2008, 7, 981-982.	4.9	40
213	Establishment of an Effective Acute Stroke Telemedicine Program for Australia: Protocol for the Victorian Stroke Telemedicine Project. International Journal of Stroke, 2014, 9, 252-258.	2.9	40
214	Response to Late-Window Endovascular Revascularization Is Associated With Collateral Status in Basilar Artery Occlusion. Stroke, 2019, 50, 1415-1422.	1.0	40
215	A review of global coagulation assays — Is there a role in thrombosis risk prediction?. Thrombosis Research, 2019, 179, 45-55.	0.8	40
216	Carotid Occlusive Disease. Archives of Neurology, 1982, 39, 687.	4.9	39

#	Article	IF	CITATIONS
217	Dextran reduces embolic signals after carotid endarterectomy. Annals of Neurology, 2001, 50, 544-547.	2.8	38
218	Performance of bedside stroke recognition tools in discriminating childhood stroke from mimics. Neurology, 2016, 86, 2154-2161.	1.5	38
219	Circadian Biology and Stroke. Stroke, 2021, 52, 2180-2190.	1.0	38
220	The Functional Neuroanatomy and Long-Term Reproducibility of Brain Activation Associated with a Simple Finger Tapping Task in Older Healthy Volunteers: A Serial PET Study. NeuroImage, 2000, 11, 124-144.	2.1	37
221	Possible Determinants of Early Microembolism After Carotid Endarterectomy. Stroke, 2002, 33, 2082-2085.	1.0	37
222	Aortic Arch Atheroma. International Journal of Stroke, 2006, 1, 74-80.	2.9	37
223	Riskâ€ødjusted hospital mortality rates for stroke: evidence from the Australian Stroke Clinical Registry (AuSCR). Medical Journal of Australia, 2017, 206, 345-350.	0.8	37
224	Limiting Neurological Damage After Stroke. Drugs and Aging, 1999, 14, 11-39.	1.3	36
225	The Risk of Intracerebral Haemorrhage with Smoking. Cerebrovascular Diseases, 1999, 9, 34-39.	0.8	36
226	Multimodality Imaging: Introduction. Stroke, 2004, 35, 2632-2634.	1.0	36
227	Digital Map of Posterior Cerebral Artery Infarcts Associated With Posterior Cerebral Artery Trunk and Branch Occlusion. Stroke, 2007, 38, 1805-1811.	1.0	36
228	Validity of Acute Stroke Lesion Volume Estimation by Diffusion-Weighted Imaging–Alberta Stroke Program Early Computed Tomographic Score Depends on Lesion Location in 496 Patients With Middle Cerebral Artery Stroke. Stroke, 2014, 45, 3583-3588.	1.0	36
229	Impact of Computed Tomography Perfusion Imaging on the Response to Tenecteplase in Ischemic Stroke. Circulation, 2017, 135, 440-448.	1.6	36
230	Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. International Journal of Stroke, 2018, 13, 175-189.	2.9	36
231	Air-Mobile Stroke Unit for access to stroke treatment in rural regions. International Journal of Stroke, 2018, 13, 568-575.	2.9	35
232	The Use of PWI and DWI Measures in the Design of "Proofâ€ofâ€Concept―Stroke Trials. Journal of Neuroimaging, 2004, 14, 123-132.	1.0	34
233	Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke. Expert Opinion on Pharmacotherapy, 2006, 7, 1571-1581.	0.9	34
234	A Topographic Study of the Evolution of the MR DWI/PWI Mismatch Pattern and Its Clinical Impact. Stroke, 2011, 42, 1596-1601.	1.0	34

#	Article	IF	CITATIONS
235	Frequent Early Cardiac Complications Contribute to Worse Stroke Outcome in Atrial Fibrillation. Cerebrovascular Diseases, 2011, 32, 454-460.	0.8	34
236	A Pathway Proteomic Profile of Ischemic Stroke Survivors Reveals Innate Immune Dysfunction in Association with Mild Symptoms of Depression – A Pilot Study. Frontiers in Neurology, 2016, 7, 85.	1.1	34
237	Increased work and social engagement is associated with increased stroke specific quality of life in stroke survivors at 3Âmonths and 12 months post-stroke: a longitudinal study of an Australian stroke cohort. Topics in Stroke Rehabilitation, 2017, 24, 405-414.	1.0	34
238	Early mobilization and quality of life after stroke. Neurology, 2019, 93, e717-e728.	1.5	34
239	The functional magnetic resonance imaging hemodynamic response to faces remains stable until the ninth decade. Neurolmage, 2003, 20, 520-528.	2.1	33
240	Trial Application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to Assist Priority Setting in Stroke. Stroke, 2004, 35, 1041-1046.	1.0	33
241	Subacute Ischemic Stroke Is Associated With Focal $\langle \sup 11 \rangle$ C PiB Positron Emission Tomography Retention But Not With Global Neocortical AÎ ² Deposition. Stroke, 2012, 43, 1341-1346.	1.0	33
242	The Association between Lesion Location and Functional Outcome after Ischemic Stroke. International Journal of Stroke, 2015, 10, 1270-1276.	2.9	33
243	Positron Emission Tomographic Imaging in Stroke. Stroke, 2016, 47, 113-119.	1.0	33
244	Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke. JAMA Neurology, 2017, 74, 1328.	4.5	33
245	Improving acute stroke care in regional hospitals: clinical evaluation of the Victorian Stroke Telemedicine program. Medical Journal of Australia, 2020, 212, 371-377.	0.8	33
246	Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management. JAMA Neurology, 2022, 79, 281.	4.5	33
247	Evidenceâ€based care and outcomes of acute stroke managed in hospital specialty units. Medical Journal of Australia, 2003, 178, 318-323.	0.8	32
248	Expediting MRI-Based Proof-of-Concept Stroke Trials Using an Earlier Imaging End Point. Stroke, 2009, 40, 1353-1358.	1.0	32
249	Role of neuroimaging in promoting longâ€term recovery from ischemic stroke. Journal of Magnetic Resonance Imaging, 2010, 32, 756-772.	1.9	32
250	Stroke Rehabilitation in China: A Systematic Review and Meta-Analysis. International Journal of Stroke, 2014, 9, 494-502.	2.9	32
251	Endovascular thrombectomy for stroke: current best practice and future goals. Stroke and Vascular Neurology, 2016, 1, 16-22.	1.5	32
252	Economic evaluation of the Melbourne Mobile Stroke Unit. International Journal of Stroke, 2021, 16, 466-475.	2.9	32

#	Article	IF	CITATIONS
253	Warfarin for atrial fibrillation: the end of an era?. Lancet Neurology, The, 2004, 3, 305-308.	4.9	31
254	Validating a Local Arterial Input Function Method for Improved Perfusion Quantification in Stroke. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 2189-2198.	2.4	31
255	Hypertension and Experimental Stroke Therapies. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1141-1147.	2.4	31
256	Telephone follow-up was more expensive but more efficient than postal in a national stroke registry. Journal of Clinical Epidemiology, 2013, 66, 896-902.	2.4	31
257	Maximising data value and avoiding data waste: a validation study in stroke research. Medical Journal of Australia, 2019, 210, 27-31.	0.8	31
258	Cost-Effectiveness of Tenecteplase Before Thrombectomy for Ischemic Stroke. Stroke, 2020, 51, 3681-3689.	1.0	31
259	Positron imaging in ischemic stroke disease. Annals of Neurology, 1984, 15, 126-130.	2.8	30
260	Cerebral βâ€amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activatorâ€related hemorrhage. Annals of Neurology, 2010, 68, 959-962.	2.8	30
261	Moving Beyond a Single Perfusion Threshold to Define Penumbra. Stroke, 2012, 43, 1548-1555.	1.0	30
262	Practical management of patients on apixaban: a consensus guide. Thrombosis Journal, 2013, 11, 27.	0.9	30
263	Healthy Life-Year Costs of Treatment Speed From Arrival to Endovascular Thrombectomy in Patients With Ischemic Stroke. JAMA Neurology, 2021, 78, 709.	4.5	30
264	Why Lacunar Syndromes Are Different and Important. Stroke, 2004, 35, 1780-1781.	1.0	29
265	State of Acute Endovascular Therapy. Stroke, 2015, 46, 1727-1734.	1.0	29
266	Utility of the Hospital Frailty Risk Score Derived From Administrative Data and the Association With Stroke Outcomes. Stroke, 2021, 52, 2874-2881.	1.0	29
267	Should the MATCH Results Be Extrapolated to All Stroke Patients and Affect Ongoing Trials Evaluating Clopidogrel Plus Aspirin?. Stroke, 2004, 35, 2606-2608.	1.0	28
268	Advances in Penumbra Imaging with MR. Cerebrovascular Diseases, 2004, 17, 23-27.	0.8	28
269	Fluid-Attenuated Inversion Recovery Hyperintensity in Acute Ischemic Stroke May Not Predict Hemorrhagic Transformation. Cerebrovascular Diseases, 2011, 32, 401-405.	0.8	28

Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic) Tj ETQq0 0 **Q.6**gBT /Ovæslock 10 Transient Ischemic)

16

270

#	Article	IF	CITATIONS
271	Longitudinal changes in activity participation in the first year post-stroke and association with depressive symptoms. Disability and Rehabilitation, 2019, 41, 2548-2555.	0.9	28
272	Readmissions after stroke: linked data from the Australian Stroke Clinical Registry and hospital databases. Medical Journal of Australia, 2015, 203, 102-106.	0.8	27
273	Better outcomes for hospitalized patients with TIA when in stroke units. Neurology, 2016, 86, 2042-2048.	1.5	27
274	Sexual Dimorphism of Resting-State Network Connectivity in Healthy Ageing. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2019, 74, 1121-1131.	2.4	27
275	Greater effect of stroke thrombolysis in the presence of arterial obstruction. Annals of Neurology, 2011, 70, 601-605.	2.8	26
276	Thrombolysis in the Developing World: Is There a Role for Streptokinase?. International Journal of Stroke, 2013, 8, 560-565.	2.9	26
277	Multi-Modal CT in Acute Stroke: Wait for a Serum Creatinine before Giving Intravenous Contrast? No!. International Journal of Stroke, 2015, 10, 1014-1017.	2.9	26
278	Contralesional Thalamic Surface Atrophy and Functional Disconnection 3 Months after Ischemic Stroke. Cerebrovascular Diseases, 2015, 39, 232-241.	0.8	26
279	Early neurological stability predicts adverse outcome after acute ischemic stroke. International Journal of Stroke, 2016, 11, 882-889.	2.9	26
280	†Out of pocket' costs to stroke patients during the first year after stroke – results from the North East Melbourne Stroke Incidence Study. Journal of Clinical Neuroscience, 2004, 11, 134-137.	0.8	25
281	Reproducible activation in BA2, 1 and 3 b associated with texture discrimination in healthy volunteers over time. NeuroImage, 2008, 39, 40-51.	2.1	25
282	REPRINT: Good Laboratory Practice: Preventing Introduction of Bias at the Bench. International Journal of Stroke, 2009, 4, 3-5.	2.9	25
283	Stroke: Working toward a Prioritized World Agenda. Cerebrovascular Diseases, 2010, 30, 127-147.	0.8	25
284	Multicenter, Prospective, Controlled, Before-and-After, Quality Improvement Study (Stroke123) of Acute Stroke Care. Stroke, 2019, 50, 1525-1530.	1.0	25
285	Heterogeneity in Infarct Patterns and Clinical Outcomes Following Internal Carotid Artery Occlusion. Archives of Neurology, 2009, 66, 1523-8.	4.9	24
286	STroke imAging pRevention and Treatment (START): A Longitudinal Stroke Cohort Study: Clinical Trials Protocol. International Journal of Stroke, 2015, 10, 636-644.	2.9	24
287	Same Intervention–Different Reorganization. Neurorehabilitation and Neural Repair, 2016, 30, 988-1000.	1.4	24
288	Factors associated with time to independent walking recovery post-stroke. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 702-708.	0.9	24

#	Article	IF	CITATIONS
289	Comparative effects of age on limbic and scalp P3. Electroencephalography and Clinical Neurophysiology - Evoked Potentials, 1989, 74, 385-393.	2.0	23
290	Antithrombotic Treatment of Embolic Stroke of Undetermined Source. Stroke, 2020, 51, 1758-1765.	1.0	23
291	Mitochondrial DNA polymorphism in substantia nigra. Journal of the Neurological Sciences, 1996, 144, 204-211.	0.3	22
292	Heparin in Stroke: Not for Most, but the Controversy Lingers. Stroke, 2003, 34, 232-233.	1.0	22
293	Aortic arch atheroma and the risk of stroke. Current Atherosclerosis Reports, 2006, 8, 343-346.	2.0	22
294	Statistical Analysis Plan (SAP) for a Very Early Rehabilitation Trial (AVERT): An International Trial to Determine the Efficacy and Safety of Commencing out of Bed Standing and Walking Training (Very) Tj ETQq0 0 C Stroke, 2015, 10, 23-24.	rgBT /Ov	erlock 10 Tf 5
295	Transitioning from a single-site pilot project to a state-wide regional telehealth service: The experience from the Victorian Stroke Telemedicine programme. Journal of Telemedicine and Telecare, 2017, 23, 850-855.	1.4	22
296	The Capsular Warning Syndrome The High Risk of Early Stroke. Cerebrovascular Diseases, 1996, 6, 202-207.	0.8	21
297	Can the Time Window for Administration of Thrombolytics in Stroke be Increased?. CNS Drugs, 2003, 17, 995-1011.	2.7	21
298	Neurologist, Internist, or Strokologist?. Stroke, 2003, 34, 2765-2765.	1.0	21
299	Fragmentation of the Classical Magnetic Resonance Mismatch "Penumbral―Pattern With Time. Stroke, 2009, 40, 3752-3757.	1.0	21
300	Regional fMRI brain activation does correlate with global brain volume. Brain Research, 2009, 1259, 17-25.	1.1	21
301	What is Stroke Symptom Knowledge?. International Journal of Stroke, 2014, 9, 48-52.	2.9	21
302	Differentiating arterial ischaemic stroke from migraine in the paediatric emergency department. Developmental Medicine and Child Neurology, 2018, 60, 1117-1122.	1.1	21
303	Identification of brain region for coordinating speech articulation. Lancet, The, 1997, 349, 221-222.	6.3	20
304	Penumbral topography in human stroke: methodology and validation of the †Penumbragram'. Neurolmage, 2004, 21, 1252-1259.	2.1	20
305	MR Mismatch and Thrombolysis. Stroke, 2009, 40, 2910-2910.	1.0	20
306	NXY-059, a Failed Stroke Neuroprotectant, Offers No Protection to Stem Cell-Derived Human Neurons. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 2158-2165.	0.7	20

#	Article	IF	CITATIONS
307	Comparative Analysis of Markers of Mass Effect after Ischemic Stroke. Journal of Neuroimaging, 2018, 28, 530-534.	1.0	20
308	Prehospital idarucizumab prior to intravenous thrombolysis in a mobile stroke unit. International Journal of Stroke, 2019, 14, 265-269.	2.9	20
309	Patterns of Infarction on MRI in Patients With Acute Ischemic Stroke and Cardio-Embolism: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2020, 11, 606521.	1.1	20
310	Streptokinase Increases Luxury Perfusion After Stroke. Stroke, 1996, 27, 1524-1529.	1.0	20
311	Endovascular Thrombectomy and Stroke Physicians. Stroke, 2017, 48, 2042-2044.	1.0	19
312	Reduction in retained activity participation is associated with depressive symptoms 3 months after mild stroke: An observational cohort study. Journal of Rehabilitation Medicine, 2017, 49, 120-127.	0.8	19
313	DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval versus Standard Bridging Therapy. Journal of Stroke, 2022, 24, 57-64.	1.4	19
314	Reduced Risk of Intracerebral Hemorrhage With Dynamic Recreational Exercise but Not With Heavy Work Activity. Stroke, 2002, 33, 559-564.	1.0	18
315	Is Carotid Angiography Necessary? Editors Disagree. Stroke, 2003, 34, 1819-1819.	1.0	18
316	Development and application of Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS): An Australian economic model for stroke. International Journal of Technology Assessment in Health Care, 2005, 21, 499-505.	0.2	18
317	Extracranial Arterial Dissection. Stroke, 2005, 36, 2043-2044.	1.0	18
318	â€~Salvaged' Stroke Ischaemic Penumbra Shows Significant Injury: Studies with the Hypoxia Tracer FMISO. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 934-943.	2.4	18
319	Exploring the benefits of a stroke telemedicine programme: An organisational and societal perspective. Journal of Telemedicine and Telecare, 2016, 22, 489-494.	1.4	18
320	Differences in Characteristics and Outcomes Between Asian and Non-Asian Patients in the TIAregistry.org. Stroke, 2017, 48, 1779-1787.	1.0	18
321	Integrating acute stroke telemedicine consultations into specialists' usual practice: a qualitative analysis comparing the experience of Australia and the United Kingdom. BMC Health Services Research, 2017, 17, 751.	0.9	18
322	Treatment with exenatide in acute ischemic stroke trial protocol: A prospective, randomized, open label, blinded end-point study of exenatide vs. standard care in post stroke hyperglycemia. International Journal of Stroke, 2018, 13, 857-862.	2.9	18
323	Clusterâ€Randomized Trial of Thrombolysis Implementation Support in Metropolitan and Regional Australian Stroke Centers: Lessons for Individual and Systems Behavior Change. Journal of the American Heart Association, 2020, 9, e012732.	1.6	18
324	Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney International, 2021, 99, 466-474.	2.6	18

#	Article	IF	Citations
325	Patent Foramen Ovale and Stroke: Closure by Further Randomized Trial Is Required!. Stroke, 2004, 35, 806-806.	1.0	17
326	Neuroprotection: Still Achievable in Humans. Stroke, 2008, 39, 525-525.	1.0	17
327	AVERT2(a very early rehabilitation trial, a very effective reproductive trigger): retrospective observational analysis of the number of babies born to trial staff. BMJ, The, 2015, 351, h6432.	3.0	17
328	Exploring threats to generalisability in a large international rehabilitation trial (AVERT). BMJ Open, 2015, 5, e008378.	0.8	17
329	Refining the ischemic penumbra with topography. International Journal of Stroke, 2018, 13, 277-284.	2.9	17
330	Aeromedical Retrieval for Stroke in Australia. Cerebrovascular Diseases, 2020, 49, 334-340.	0.8	17
331	Midline Shift Greater than 3Âmm Independently Predicts Outcome After Ischemic Stroke. Neurocritical Care, 2022, 36, 46-51.	1.2	17
332	Endovascular Thrombectomy Versus Medical Management in Isolated ⟨scp⟩M2⟨ scp⟩ Occlusions: Pooled ⟨scp⟩Patientâ€Level⟨ scp⟩ Analysis from the ⟨scp⟩EXTENDâ€LA⟨ scp⟩ Trials, ⟨scp⟩INSPIRE⟨ scp⟩, and ⟨scp⟩SELECT⟨ scp⟩ Studies. Annals of Neurology, 2022, 91, 629-639.	2.8	17
333	PWI/DWI Mismatch: Better Definition Required. Stroke, 2003, 34, e215-6; author reply e215-6.	1.0	16
334	Characterization of Fluoromisonidazole Binding in Stroke. Stroke, 2006, 37, 1862-1867.	1.0	16
335	The Role of Bolus Delay and Dispersion in Predictor Models for Stroke. Stroke, 2012, 43, 1025-1031.	1.0	16
336	Reperfusion after $4 \hat{A} \cdot 5$ Hours Reduces Infarct Growth and Improves Clinical Outcomes. International Journal of Stroke, 2014, 9, 266-269.	2.9	16
337	Prediction of final infarct volume on subacute MRI by quantifying cerebral edema in ischemic stroke. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3077-3084.	2.4	16
338	Hyperacute changes in blood mRNA expression profiles of rats after middle cerebral artery occlusion: Towards a stroke time signature. PLoS ONE, 2018, 13, e0206321.	1.1	16
339	Mobile Stroke Units Facilitate Prehospital Management of Intracerebral Hemorrhage. Stroke, 2021, 52, 3163-3166.	1.0	16
340	Regional and temporal effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine uptake sites in mouse brain. Journal of the Neurological Sciences, 1987, 81, 261-271.	0.3	15
341	Surgical damage stimulates proliferation of dopamine uptake sites in normal mouse brain. Brain Research, 1993, 622, 285-288.	1.1	15
342	Intraâ€arterial streptokinase in acute ischaemic stroke; A pilot study. Medical Journal of Australia, 1993, 159, 331-334.	0.8	15

#	Article	IF	CITATIONS
343	The Pace Pilot Study: 12â€Month Results and Implications for Future Primary Prevention Trials in the Elderly. Journal of the American Geriatrics Society, 1994, 42, 643-647.	1.3	15
344	Dopaminergic responses to striatal damage. Journal of the Neurological Sciences, 1996, 139, 125-130.	0.3	15
345	Neuroprotection: Establishing Proof of Concept in Human Stroke. Stroke, 2002, 33, 309-310.	1.0	15
346	Stroke and Cholesterol. Stroke, 2004, 35, 1526-1526.	1.0	15
347	Serial Functional Imaging Poststroke Reveals Visual Cortex Reorganization. Neurorehabilitation and Neural Repair, 2009, 23, 150-159.	1.4	15
348	Characterisation of the timing of binding of the hypoxia tracer FMISO after stroke. Brain Research, 2009, 1288, 135-142.	1.1	15
349	The Hidden Mismatch. Stroke, 2011, 42, 662-668.	1.0	15
350	Operations Research for stroke care systems: An opportunity for The Science of Better to do much better. Operations Research for Health Care, 2012, 1, 6-15.	0.8	15
351	Optimizing Systems of Care for Endovascular Thrombectomy in Ischemic Stroke. Circulation, 2017, 136, 2322-2324.	1.6	15
352	Treatment and Outcomes of Working Aged Adults with Stroke: Results from a National Prospective Registry. Neuroepidemiology, 2017, 49, 113-120.	1.1	15
353	Improving quality and outcomes of stroke care in hospitals: Protocol and statistical analysis plan for the Stroke123 implementation study. International Journal of Stroke, 2018, 13, 96-106.	2.9	15
354	Five-Year Prognosis After TIA or Minor Ischemic Stroke in Asian and Non-Asian Populations. Neurology, 2021, 96, e54-e66.	1.5	15
355	Predictive Performance of a Polygenic Risk Score for Incident Ischemic Stroke in a Healthy Older Population. Stroke, 2021, 52, 2882-2891.	1.0	15
356	Neurodegeneration Over 3 Years Following Ischaemic Stroke: Findings From the Cognition and Neocortical Volume After Stroke Study. Frontiers in Neurology, 2021, 12, 754204.	1.1	15
357	Smoking as a Risk Factor for Stroke. Cerebrovascular Diseases, 1993, 3, 129-138.	0.8	14
358	Blood Pressure Reduction and ACE Inhibition in Secondary Stroke Prevention: Mechanism Uncertain. Stroke, 2003, 34, 1335-1336.	1.0	14
359	The role of blood pressure lowering before and after stroke. Current Opinion in Neurology, 2003, 16, 81-86.	1.8	14
360	Strategies to improve outcomes after acute stroke. Medical Journal of Australia, 2003, 178, 309-310.	0.8	14

#	Article	IF	CITATIONS
361	Steroids for Stroke: Another Potential Therapy Discarded Prematurely?. Stroke, 2004, 35, 230-231.	1.0	14
362	Smoking as a Crucial Independent Determinant of Stroke. Tobacco Induced Diseases, 2004, 2, 67.	0.3	14
363	Patients With Small, Asymptomatic, Unruptured Intracranial Aneurysms and No History of Subarachnoid Hemorrhage Should Be Treated Conservatively. Stroke, 2005, 36, 407-407.	1.0	14
364	Intraobserver and Interobserver Variability of Transesophageal Echocardiography in Aortic Arch Atheroma Measurement. Journal of the American Society of Echocardiography, 2008, 21, 129-133.	1.2	14
365	Estimating the Prevalence of Sleep-Disordered Breathing in Community-Based, Long-Term Stroke Survivors Using a Validated Predictive Model. Cerebrovascular Diseases, 2008, 26, 441-446.	0.8	14
366	Human In Vitro Models of Ischaemic Stroke: a Test Bed for Translation. Translational Stroke Research, 2012, 3, 306-309.	2.3	14
367	Perfusion/Diffusion Mismatch Is Valid and Should Be Used for Selecting Delayed Interventions. Translational Stroke Research, 2012, 3, 188-197.	2.3	14
368	Accuracy and Reliability of Stroke Diagnosis in the Pediatric Emergency Department. Stroke, 2017, 48, 1198-1202.	1.0	14
369	Prescription of antihypertensive medication at discharge influences survival following stroke. Neurology, 2018, 90, e745-e753.	1.5	14
370	The Use of PWI and DWI Measures in the Design of "Proof-of-Concept―Stroke Trials. , 2004, 14, 123-132.		14
371	Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study. Stroke, 2022, 53, 779-787.	1.0	14
372	Thrombectomy versus Medical Management in Mild Strokes due to Large Vessel Occlusion: Exploratory Analysis from the EXTENDâ€A Trials and a Pooled International Cohort. Annals of Neurology, 2022, 92, 364-378.	2.8	14
373	Recommendations for the Relationship Between Sponsors and Investigators in the Design and Conduct of Clinical Stroke Trials. Stroke, 2003, 34, 1041-1045.	1.0	13
374	Effective Prophylaxis for Deep Venous Thrombosis After Stroke. Stroke, 2004, 35, 2910-2910.	1.0	13
375	Comment on ITAIS. International Journal of Stroke, 2009, 4, 49-53.	2.9	13
376	Patients with Single Distal MCA Perfusion Lesions Have a High Rate of Good Outcome with or without Reperfusion. International Journal of Stroke, 2014, 9, 156-159.	2.9	13
377	A collaborative sequential meta-analysis of individual patient data from randomized trials of endovascular therapy and tPA vs. tPA alone for acute ischemic stroke: <u>T</u> h <u>R</u> omb <u>E</u> ctomy <u>A</u> nd <u>t</u> PA (TREAT) analysis: statistical analysis plan for a sequential meta-analysis plan for a sequential meta-analysis plan for a sequential meta-analysis.	2.9	13
378	International Journal of Stroke, 2015, 10, 136-144. Retrospective review on isolated distal deep vein thrombosis (IDDVT) — A benign entity or not?. Thrombosis Research, 2016, 142, 11-16.	0.8	13

#	Article	IF	Citations
379	Symptomatic Patients Remain at Substantial Risk of Arterial Disease Complications Before and After Endarterectomy or Stenting. Stroke, 2017, 48, 1005-1010.	1.0	13
380	Quality of Life Is Poorer for Patients With Stroke Who Require an Interpreter. Stroke, 2018, 49, 761-764.	1.0	13
381	Look closer: The multidimensional patterns of post-stroke burden behind the modified Rankin Scale. International Journal of Stroke, 2021, 16, 420-428.	2.9	13
382	More (or less) on Broca. Lancet, The, 1999, 353, 1031-1032.	6. 3	12
383	Quality of stroke care within a hospital: effects of a mobile stroke service. Medical Journal of Australia, 2005, 182, 160-163.	0.8	12
384	Individuals with firstâ€ever clinical presentation of a lacunar infarction syndrome: Is there an increased likelihood of developing mild cognitive impairment in the first 12 months after stroke?. Journal of Neuropsychology, 2008, 2, 373-385.	0.6	12
385	Risk Factors and Aetiology of Cerebral Infarction in Young Adults: a Comparative Study between Malaysia and Australia. International Journal of Stroke, 2010, 5, 428-430.	2.9	12
386	Outcomes for Patients With In-Hospital Stroke: A Multicenter Study From the Australian Stroke Clinical Registry (AuSCR). Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 1302-1310.	0.7	12
387	Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study. International Journal of Stroke, 2020, 15, 567-572.	2.9	12
388	Association of Reperfusion After Thrombolysis With Clinical Outcome Across the 4.5- to 9-Hours and Wake-up Stroke Time Window. JAMA Neurology, 2021, 78, 236.	4. 5	12
389	Stroke incidence and subtypes in Aboriginal people in remote Australia: a healthcare network population-based study. BMJ Open, 2020, 10, e039533.	0.8	12
390	Indigenous Australians have a greater prevalence of heart, stroke, and vascular disease, are younger at death, with higher hospitalisation and more aeromedical retrievals from remote regions. EClinicalMedicine, 2021, 42, 101181.	3.2	12
391	Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomised placebo-controlled double-blind multicentre trial. Stroke and Vascular Neurology, 2022, 7, 158-165.	1.5	12
392	Disorders of memory in vertebrobasilar disease. Journal of Clinical Neuropsychology, 1980, 2, 267-276.	1.2	11
393	Scope of Preclinical Testing Versus Quality Control Within Experiments. Stroke, 2009, 40, e497.	1.0	11
394	Multiattribute Selection of Acute Stroke Imaging Software Platform for Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND) Clinical Trial. International Journal of Stroke, 2013, 8, 204-210.	2.9	11
395	Hospital organizational context and delivery of evidence-based stroke care: a cross-sectional study. Implementation Science, 2019, 14, 6.	2.5	11
396	Cardiovascular risk prediction in healthy older people. GeroScience, 2022, 44, 403-413.	2.1	11

#	Article	IF	CITATIONS
397	Stroke Unit Design: High Tech Versus Low Tech. Stroke, 2004, 35, 1021-1021.	1.0	10
398	Unruptured Brain Arteriovenous Malformations. Stroke, 2007, 38, 3312-3312.	1.0	10
399	Digital Probabilistic Atlas of the Border Region between the Middle and Posterior Cerebral Arteries. Cerebrovascular Diseases, 2009, 27, 529-536.	0.8	10
400	An evaluation of global coagulation assays in myeloproliferative neoplasm. Blood Coagulation and Fibrinolysis, 2018, 29, 300-306.	0.5	10
401	Acute Routine Leukocyte and Neutrophil Counts Are Predictive of Poststroke Recovery at 3 and 12 Months Poststroke: An Exploratory Study. Neurorehabilitation and Neural Repair, 2020, 34, 844-855.	1.4	10
402	Global coagulation assays in healthy controls: are there compensatory mechanisms within the coagulation system?. Journal of Thrombosis and Thrombolysis, 2021, 52, 610-619.	1.0	10
403	The role of blood pressure lowering before and after stroke. Current Opinion in Neurology, 2003, 16, 81-6.	1.8	10
404	Seizure associated with mefloquine for malaria prophylaxis. Medical Journal of Australia, 1994, 161, 453-453.	0.8	9
405	The Bayesian Principle. Stroke, 2005, 36, 1623-1624.	1.0	9
406	Stroke Drug Development. Stroke, 2005, 36, 2326-2326.	1.0	9
407	Stroke and nutrition: FOOD for thought. Lancet, The, 2005, 365, 729-730.	6.3	9
408	fMRI Demonstrates Diaschisis in the Extrastriate Visual Cortex. Stroke, 2007, 38, 2360-2363.	1.0	9
409	Chapter 27 Lacunes and lacunar syndromes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 93, 559-575.	1.0	9
410	History of Animal Models of Stroke. International Journal of Stroke, 2011, 6, 77-78.	2.9	9
411	How Much Diffusion Lesion Reversal Occurs after Treatment within Three-Hours of Stroke Onset?. International Journal of Stroke, 2013, 8, 329-330.	2.9	9
412	Vessel Occlusion, Penumbra, and Reperfusion ââ,¬â€œ Translating Theory to Practice. Frontiers in Neurology, 2014, 5, 194.	1.1	9
413	Testing Devices for the Prevention and Treatment of Stroke and its Complications. International Journal of Stroke, 2014, 9, 683-695.	2.9	9
414	Discovery and Longitudinal Evaluation of Candidate Biomarkers for Ischaemic Stroke by Mass Spectrometry-Based Proteomics. Biomarker Insights, 2017, 12, 117727191774921.	1.0	9

#	Article	IF	CITATIONS
415	Association between pre-treatment perfusion profile and cerebral edema after reperfusion therapies in ischemic stroke. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2887-2896.	2.4	9
416	Smoking as a Risk Factor for Cortical Ischaemia Presumably due to Carotid Occlusive Disease. Neuroepidemiology, 1993, 12, 141-147.	1.1	8
417	Carotid Stenting Is Unproven: Randomization Is a Must. Stroke, 2002, 33, 2522-2523.	1.0	8
418	Surgery for Intracerebral Hemorrhage: An Evidence-Poor Zone. Stroke, 2003, 34, 1569-1570.	1.0	8
419	Surgical Decompression for Malignant Middle Cerebral Artery Infarction: A Challenge to Conventional Thinking. Stroke, 2003, 34, 2307-2307.	1.0	8
420	Using Mismatch on MRI to Select Thrombolytic Responders. Stroke, 2005, 36, 1100-1101.	1.0	8
421	Assessment of Suitability of Thrombolysis in Middle Cerebral Artery Infarction: A Proof of Concept Study of a Stereologically-Based Technique. Cerebrovascular Diseases, 2007, 24, 321-327.	0.8	8
422	Family physician decisions following stroke symptom onset and delay times to ambulance call. BMC Family Practice, 2011, 12, 82.	2.9	8
423	Does Abnormal Circadian Blood Pressure Pattern Really Matter in Patients With Transient Ischemic Attack or Minor Stroke?. Stroke, 2014, 45, 865-867.	1.0	8
424	Uric acid for stroke: glimmer of hope or false dawn?. Lancet Neurology, The, 2014, 13, 440-441.	4.9	8
425	Selection for Delayed Intravenous Alteplase Treatment Based on a Prognostic Score. International Journal of Stroke, 2015, 10, 90-94.	2.9	8
426	Parental Care–Seeking Behavior and Prehospital Timelines of Care in Childhood Arterial Ischemic Stroke, 2016, 47, 2638-2640.	1.0	8
427	Association between baseline peri-infarct magnetic resonance spectroscopy and regional white matter atrophy after stroke. Neuroradiology, 2016, 58, 3-10.	1.1	8
428	Venous thromboembolism management in Northeast Melbourne: how does it compare to international guidelines and data?. Internal Medicine Journal, 2017, 47, 1034-1042.	0.5	8
429	Googling Boundaries for Operating Mobile Stroke Unit for Stroke Codes. Frontiers in Neurology, 2019, 10, 331.	1.1	8
430	Safety and Efficacy of Tenecteplase in Older Patients With Large Vessel Occlusion: A Pooled Analysis of the EXTEND-IA TNK Trials. Neurology, 2022, , 10.1212/WNL.00000000013302.	1.5	8
431	A magnetoimpedance biosensor microfluidic platform for detection of glial fibrillary acidic protein in blood for acute stroke classification. Biosensors and Bioelectronics, 2022, 211, 114410.	5.3	8
432	Therapy in cerebrovascular disease: current status and future directions. Medical Journal of Australia, 1991, 155, 563-571.	0.8	7

#	Article	IF	Citations
433	Rationale for a Primary Prevention Study Using Lowâ€Dose Aspirin To Prevent Coronary and Cerebrovascular Disease in the Elderly. Journal of the American Geriatrics Society, 1991, 39, 484-491.	1.3	7
434	Haematological profile of healthy elderly Australians. Medical Journal of Australia, 1992, 157, 96-100.	0.8	7
435	CT Screening for Thrombolysis: Uncertainties Remain. Stroke, 2003, 34, 822-823.	1.0	7
436	MRI and stroke: why has it taken so long?. Lancet, The, 2007, 369, 252-254.	6.3	7
437	Glucose and the ischaemic brain: too much of a good thing?. Lancet Neurology, The, 2007, 6, 380-381.	4.9	7
438	The ECASS III Results and the Tpa Paradox. International Journal of Stroke, 2009, 4, 17-18.	2.9	7
439	Correlated Resting-State Functional MRI Activity of Frontostriatal, Thalamic, Temporal, and Cerebellar Brain Regions Differentiates Stroke Survivors with High Compared to Low Depressive Symptom Scores. Neural Plasticity, 2019, 2019, 1-12.	1.0	7
440	Longitudinal Stroke Recovery Associated With Dysregulation of Complement System—A Proteomics Pathway Analysis. Frontiers in Neurology, 2020, 11, 692.	1.1	7
441	Fatal and Nonfatal Events Within 14 days After Early, Intensive Mobilization Poststroke. Neurology, 2021, 96, .	1.5	7
442	Global coagulation assays in patients with diabetes mellitus. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12611.	1.0	7
443	Global coagulation assays in hypercoagulable states. Journal of Thrombosis and Thrombolysis, 2022, 54, 132-144.	1.0	7
444	Aspirin Therapy Should Be First Line:. Stroke, 2002, 33, 2139-2140.	1.0	6
445	High Intensity Transient Signals in Patients with Carotid Stenosis May Persist after Carotid Endarterectomy. Cerebrovascular Diseases, 2004, 17, 123-127.	0.8	6
446	Life after DIAS II. International Journal of Stroke, 2007, 2, 236-237.	2.9	6
447	Secondary prevention of stroke – Authors' reply. Lancet, The, 2008, 372, 1036.	6.3	6
448	Paracentral Strip Infarcts of the Middle Cerebral Artery: Borderzone Ischaemia or Cortical Artery Occlusion?. Cerebrovascular Diseases, 2009, 27, 215-222.	0.8	6
449	Expanded indications for stroke thrombolysis—what next?. Nature Reviews Neurology, 2012, 8, 482-483.	4.9	6
450	Extrastriate visual cortex reorganizes despite sequential bilateral occipital stroke: implications for vision recovery. Frontiers in Human Neuroscience, 2015, 9, 224.	1.0	6

#	Article	IF	Citations
451	10 Years and Going Strong!. International Journal of Stroke, 2015, 10, 1-1.	2.9	6
452	Identification of imaging selection patterns in acute ischemic stroke patients and the influence on treatment and clinical trial enrollment decision making. International Journal of Stroke, 2016, 11, 180-190.	2.9	6
453	Postoperative atrial fibrillation: Target for stroke prevention?. European Stroke Journal, 2017, 2, 222-228.	2.7	6
454	Comparing mismatch strategies for patients being considered for ischemic stroke tenecteplase trials. International Journal of Stroke, 2020, 15, 507-515.	2.9	6
455	Lindsay Symon: A giant of stroke. International Journal of Stroke, 2020, 15, 356-360.	2.9	6
456	Cerebrovascular disease and dementia. Drugs of Today, 2005, 41, 815.	0.7	6
457	Does variability in automated perfusion software outputs for acute ischemic stroke matter? Reanalysis of EXTEND perfusion imaging. CNS Neuroscience and Therapeutics, 2022, 28, 139-144.	1.9	6
458	Aortic Arch Atheroma and Stroke. Cerebrovascular Diseases, 1995, 5, 10-13.	0.8	5
459	Thunderclap Headache. Stroke, 2008, 39, 1396-1396.	1.0	5
460	Stroke in Developing Countries: The Looming Epidemic. International Journal of Stroke, 2011, 6, 97-97.	2.9	5
461	Seven Years of IJS and Working Hard to Meet the Needs of Stroke Professionals Globally. International Journal of Stroke, 2012, 7, 1-1.	2.9	5
462	Endovascular Therapy Proven for Stroke – Finally!. Heart Lung and Circulation, 2015, 24, 733-735.	0.2	5
463	Animal Models of Ischemic Stroke Versus Clinical Stroke: Comparison of Infarct Size, Cause, Location, Study Design, and Efficacy of Experimental Therapies., 2017,, 481-523.		5
464	Statistical Analysis Plan for EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND) trial. International Journal of Stroke, 2020, 15, 231-238.	2.9	5
465	Comparison of T2*GRE and DSC-PWI for hemorrhage detection in acute ischemic stroke patients: Pooled analysis of the EPITHET, DEFUSE 2, and SENSE 3 stroke studies. International Journal of Stroke, 2020, 15, 216-225.	2.9	5
466	Factors Associated With Treatment and Control of Hypertension in a Healthy Elderly Population Free of Cardiovascular Disease: A Cross-sectional Study. American Journal of Hypertension, 2020, 33, 350-361.	1.0	5
467	The impact of the DWI-FLAIR-mismatch in the ECASS-4 trial – A post hoc analysis. European Stroke Journal, 2020, 5, 370-373.	2.7	5
468	Reduced Severity of Tissue Injury Within the Infarct May Partially Mediate the Benefit of Reperfusion in Ischemic Stroke. Stroke, 2022, 53, 1915-1923.	1.0	5

#	Article	IF	CITATIONS
469	Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile) Tj ETQq1 1 0.78 superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5	0.8	T /Overlock 1 5
	hours of symptom onset to the mobile stroke unit. BMJ Open, 2022, 12, e056573.		
470	Hypertension and the risk of intracerebral haemorrhage: special considerations in patients with renal disease. Nephrology Dialysis Transplantation, 1999, 14, 2291-2292.	0.4	4
471	Ischemic Penumbra: MRI or PET. Stroke, 2003, 34, 2536-2536.	1.0	4
472	The Stroke-Prone State. Stroke, 2006, 37, 1140-1140.	1.0	4
473	The Ethics of Thrombolytic Trials Beyond 3 (or 4.5) Hours. Stroke, 2009, 40, 1545-1545.	1.0	4
474	Response to "A Graphic Reanalysis of the NINDS Trial― Annals of Emergency Medicine, 2010, 55, 227-229.	0.3	4
475	Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial. Cerebrovascular Diseases, 2018, 45, 213-220.	0.8	4
476	Using routine HbA1c measurements in stroke and the associations of dysglycaemia with stroke outcomes. Journal of Diabetes and Its Complications, 2018, 32, 1056-1061.	1.2	4
477	Global coagulation assays in patients with multiple myeloma and monoclonal gammopathy of unknown significance. Thrombosis Research, 2019, 183, 45-48.	0.8	4
478	Pre-existing Comorbidity Burden and Patient Perceived Stroke Impact. International Journal of Stroke, 2021, 16, 273-279.	2.9	4
479	Does Intravenous Thrombolysis Within 4.5 to 9 Hours Increase Clot Migration Leading to Endovascular Inaccessibility?. Stroke, 2021, 52, 1083-1086.	1.0	4
480	Factors associated with arrival by ambulance for patients with stroke: a multicentre, national data linkage study. Australasian Emergency Care, 2021, 24, 167-173.	0.7	4
481	Novel Imaging Markers of Ischemic Cerebral Edema and Its Association with Neurological Outcome. Acta Neurochirurgica Supplementum, 2016, 121, 223-226.	0.5	4
482	When Is Enough Enough?. Stroke, 2001, 32, 2710-2711.	1.0	4
483	Hypertension as a Risk Factor for Stroke Subtypes. Hypertension Research, 1994, 17, S51-S54.	1.5	4
484	Ischemic Penumbra: A Personal View. Cerebrovascular Diseases, 2021, 50, 656-665.	0.8	4
485	Thrombolytic Therapy in Acute Ischaemic Stroke. CNS Drugs, 1996, 6, 257-262.	2.7	3
486	Stroke: prediction, prevention, and outcome. Lancet Neurology, The, 2004, 3, 9.	4.9	3

#	Article	lF	Citations
487	Merci Retriever. Stroke, 2006, 37, 1343-1344.	1.0	3
488	Editorial. International Journal of Stroke, 2008, 3, 157-157.	2.9	3
489	Chronic Information-processing Changes in Individuals With a First-ever Clinical Lacunar Syndrome. Cognitive and Behavioral Neurology, 2008, 21, 236-241.	0.5	3
490	Animal Models of Stroke Versus Clinical Stroke. , 2013, , 531-568.		3
491	World Stroke Day Editorial. International Journal of Stroke, 2014, 9, 1-1.	2.9	3
492	The long-term benefits of endovascular therapy. Lancet Neurology, The, 2017, 16, 337-338.	4.9	3
493	Impact of the 2017 American Heart Association and American College of Cardiology hypertension guideline in aged individuals. Journal of Hypertension, 2020, 38, 2527-2536.	0.3	3
494	Bringing CT Scanners to the Skies: Design of a CT Scanner for an Air Mobile Stroke Unit. Applied Sciences (Switzerland), 2022, 12, 1560.	1.3	3
495	Does tranexamic acid affect intraventricular hemorrhage growth in acute ICH? An analysis of the STOP-AUST trial. European Stroke Journal, 2022, 7, 15-19.	2.7	3
496	Acute stroke: a new era?. Australian and New Zealand Journal of Medicine, 1992, 22, 3-4.	0.5	2
497	Extensive hemispheric cerebral infarction. Journal of Stroke and Cerebrovascular Diseases, 1998, 7, 398-403.	0.7	2
498	Management of Stroke in Older People; A Pharmacological Perspective. Journal of Pharmacy Practice and Research, 2000, 30, 60-65.	0.2	2
499	RE: "DOES TEA AFFECT CARDIOVASCULAR DISEASE? A META-ANALYSIS". American Journal of Epidemiology, 2002, 156, 490-490.	1.6	2
500	Controversy: The Essence of Medical Debate. Stroke, 2003, 34, 372-373.	1.0	2
501	Aspirin after intracerebral haemorrhage: probably safer than we thought. Lancet Neurology, The, 2006, 5, 288-289.	4.9	2
502	Comment on ITAIS. International Journal of Stroke, 2009, 4, 49-49.	2.9	2
503	Editorial. International Journal of Stroke, 2009, 4, 1-2.	2.9	2
504	IJS Impact Factor Jumps to 2.871 in Only Five Years!. International Journal of Stroke, 2010, 5, 341-341.	2.9	2

#	Article	IF	Citations
505	Stroke around the World. International Journal of Stroke, 2011, 6, 181-181.	2.9	2
506	IST-3: A Major Contribution to Thrombolysis Research. International Journal of Stroke, 2012, 7, 566-567.	2.9	2
507	COPE (Committee on Publishing Ethics). International Journal of Stroke, 2014, 9, 837-837.	2.9	2
508	Recruitment to trials of late thrombolysis: Lessons from the EXTEND study. Journal of Clinical Neuroscience, 2014, 21, 1215-1219.	0.8	2
509	I am woman – Saving bodies and minds. International Journal of Stroke, 2015, 10, 1-1.	2.9	2
510	Endovascular Therapy: The Dawning of a New Era. International Journal of Stroke, 2015, 10, 463-463.	2.9	2
511	Weekend hospital discharge is associated with suboptimal care and outcomes: An observational Australian Stroke Clinical Registry study. International Journal of Stroke, 2019, 14, 430-438.	2.9	2
512	Prospective analysis of stroke recognition, stroke risk factors, thrombolysis rates and outcomes in Indigenous Australians from a large rural referral hospital. Internal Medicine Journal, 2022, 52, 468-473.	0.5	2
513	TACTICS - Trial of Advanced CT Imaging and Combined Education Support for Drip and Ship: evaluating the effectiveness of an †implementation intervention' in providing better patient access to reperfusion therapies: protocol for a non-randomised controlled stepped wedge cluster trial in acute stroke. BMJ Open, 2022, 12, e055461.	0.8	2
514	Outcome prediction in large vessel occlusion ischemic stroke with or without endovascular stroke treatment: THRIVE-EVT. International Journal of Stroke, 2023, 18, 331-337.	2.9	2
515	Fibrin clot characteristics and anticoagulant response in a SARSâ€CoVâ€2â€infected endothelial model. EJHaem, 2022, 3, 326-334.	0.4	2
516	The evaluation of overall hemostatic potential assay in patients with <scp>COVID</scp> â€19 infection. International Journal of Laboratory Hematology, 2022, 44, .	0.7	2
517	Thrombolysis in acute ischaemic stroke. Journal of Clinical Neuroscience, 2001, 8, 112-115.	0.8	1
518	Immediate Anticoagulation for Acute Stroke in Atrial Fibrillation. Stroke, 2006, 37, 3056-3056.	1.0	1
519	Stenting for Middle Cerebral Artery Stenosis. Stroke, 2007, 38, 1422-1422.	1.0	1
520	Neuroprotection: where to now?. Future Neurology, 2007, 2, 513-521.	0.9	1
521	Acute Stroke Therapies: Some Unexpected Challenges. International Journal of Stroke, 2007, 2, 235-235.	2.9	1
522	Editorial. International Journal of Stroke, 2008, 3, 77-77.	2.9	1

#	Article	IF	Citations
523	EPITHET—where next? – Authors' reply. Lancet Neurology, The, 2008, 7, 571-572.	4.9	1
524	Combined Aspirin Plus Warfarin. Stroke, 2009, 40, 1946-1946.	1.0	1
525	Angiotensin Receptor Blockers and Stroke Therapy. Stroke, 2009, 40, 3163-3163.	1.0	1
526	Antiplatelet Activity. Stroke, 2009, 40, 2275-2275.	1.0	1
527	The Coming Year in Stroke: a Busy Schedule for 2010. International Journal of Stroke, 2010, 5, 137-137.	2.9	1
528	As One Door Closes, Another Opens. International Journal of Stroke, 2011, 6, 283-283.	2.9	1
529	Why should you Support the WSO?. International Journal of Stroke, 2012, 7, 103-103.	2.9	1
530	Multidisciplinary Stroke Management. International Journal of Stroke, 2012, 7, 275-275.	2.9	1
531	The Burden of Stroke and Priorities for Stroke Research. International Journal of Stroke, 2013, 8, 397-397.	2.9	1
532	Rehabilitation: The Sleeping Giant of Stroke Medicine. International Journal of Stroke, 2013, 8, 1-1.	2.9	1
533	Research Priorities. International Journal of Stroke, 2014, 9, 259-259.	2.9	1
534	New Therapies, Large Databases, and Vale Jack P. Whisnant. International Journal of Stroke, 2015, 10, 789-789.	2.9	1
535	The Impact of MR Clean. International Journal of Stroke, 2015, 10, 139-139.	2.9	1
536	New publisher, new-year, new decade. International Journal of Stroke, 2016, 11, 5-5.	2.9	1
537	NeuroRehabilitation. International Journal of Stroke, 2016, 11, 385-385.	2.9	1
538	Acute Ischemic Stroke. , 2018, , 3-21.		1
539	Extending the time window for thrombolysis. International Journal of Stroke, 2019, 14, 449-449.	2.9	1
540	Identification of barriers and enablers to rapid diagnosis along the paediatric stroke chain of recovery using Value-Focused Process Engineering. Health Systems, 2021, 10, 73-88.	0.9	1

#	Article	IF	CITATIONS
541	Screening for postâ€stroke depression: who, when and how?. Medical Journal of Australia, 2021, 215, 305-307.e1.	0.8	1
542	Acute stroke management around the world. , 2003, , 1-13.		1
543	Overview of Laboratory Studies. , 2004, , 439-447.		1
544	Abstract 153: Shorter, More Frequent Out of Bed Activity Very Early After Stroke (AVERT) is Associated With a Favorable Outcome at 3 Months. Stroke, 2016, 47, .	1.0	1
545	The Rolls Royce of MS: McAlpine's multiple sclerosis Medical Journal of Australia, 1985, 143, S26.	0.8	O
546	Comment. Journal of Clinical Neuroscience, 2000, 7, 348.	0.8	0
547	The Ninds Trial of Thrombolysis in Acute Ischaemic Stroke. Practical Neurology, 2002, 2, 178-181.	0.5	O
548	Should ximelagatran replace warfarin for stroke prevention in patients with atrial fibrillation?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 278-279.	3.3	0
549	Introductory Editorial. International Journal of Stroke, 2006, 1, 2-2.	2.9	0
550	Future advances in the treatment of acute ischemic stroke. Future Neurology, 2007, 2, 51-58.	0.9	0
551	Editorial. International Journal of Stroke, 2007, 2, 1-1.	2.9	O
552	Editorial. International Journal of Stroke, 2007, 2, 163-163.	2.9	0
553	Editorial. International Journal of Stroke, 2008, 3, 229-229.	2.9	0
554	IV and IA Thrombolytic Stroke Strategies Are Complementary. Stroke, 2009, 40, 2615-2615.	1.0	0
555	The Year in Stroke. International Journal of Stroke, 2009, 4, 421-421.	2.9	0
556	Response to Letter by Furlan. Stroke, 2009, 40, .	1.0	0
557	Stroke Diagnosis and Imaging: a Symbiotic Partnership. International Journal of Stroke, 2010, 5, 61-61.	2.9	0
558	Synergia, Conferences and Congresses: Think Tanks, Collaborations and Education!. International Journal of Stroke, 2010, 5, 237-237.	2.9	0

#	Article	IF	CITATIONS
559	Five Years under our Belt, and Counting!. International Journal of Stroke, 2010, 5, 433-433.	2.9	O
560	Clot Retrieval for Stroke. Stroke, 2010, 41, 196-196.	1.0	0
561	Six Years and Still Moving Forward. International Journal of Stroke, 2011, 6, 1-1.	2.9	O
562	Increasing Editions from Six to Eight in 2012. International Journal of Stroke, 2011, 6, 471-471.	2.9	0
563	Seizures and stroke. , 0, , 158-165.		0
564	World Stroke Day 2012: One in Six. International Journal of Stroke, 2012, 7, 535-535.	2.9	0
565	Celebrating Research!. International Journal of Stroke, 2012, 7, 605-605.	2.9	0
566	To the Young Investigator. International Journal of Stroke, 2012, 7, 185-185.	2.9	0
567	Translational Research: A Critical Point in Time. International Journal of Stroke, 2012, 7, 367-367.	2.9	0
568	Mentors. International Journal of Stroke, 2012, 7, 443-443.	2.9	0
569	The Midyear Overview 2013. International Journal of Stroke, 2013, 8, 219-219.	2.9	0
570	Standing on the Shoulders of Giants. International Journal of Stroke, 2013, 8, 59-59.	2.9	0
571	Howard Florey and neuroscience. Journal of Physiology, 2013, 591, 33-34.	1.3	O
572	European Stroke Conference, INTERACT2, and Stroke Support Organizations invited to Contribute to <i>International Journal of Stroke</i>	2.9	0
573	2014 will Bring Surprises and Improvements. International Journal of Stroke, 2013, 8, 605-605.	2.9	0
574	World Stroke Day: â€~Because I Care …'. International Journal of Stroke, 2013, 8, 1-1.	2.9	0
575	Wither II Recanalization?. International Journal of Stroke, 2013, 8, 285-285.	2.9	0
576	The Research Rolls on. International Journal of Stroke, 2013, 8, 495-495.	2.9	0

#	Article	IF	Citations
577	Hypothermia and Atrial Fibrillation. International Journal of Stroke, 2014, 9, 543-543.	2.9	O
578	Global Incidence Study. International Journal of Stroke, 2014, 9, 1-1.	2.9	0
579	Telemedicine, FAST-MAG and Participation in Clinical Trials. International Journal of Stroke, 2014, 9, 155-155.	2.9	O
580	2014, a Great Year for IJS!. International Journal of Stroke, 2014, 9, 963-963.	2.9	0
581	Animal Models, Complications of Trial Protocols, and WAKE UP Protocol. International Journal of Stroke, 2014, 9, 669-669.	2.9	0
582	Awards: What Do They Mean?. International Journal of Stroke, 2014, 9, 393-393.	2.9	O
583	Newer Anticoagulants Should Not Be Used for Off-Label Indications. Stroke, 2014, 45, 2156-2157.	1.0	O
584	Thrombectomy Trials and Implications. International Journal of Stroke, 2015, 10, 645-645.	2.9	0
585	Thrombectomy, Global Survey of the Diagnostic Evaluation and Management of Cryptogenic Ischemic Stroke, and Personalized Medicine. International Journal of Stroke, 2015, 10, 989-989.	2.9	O
586	Celebrating 10 Years of the International Journal of Stroke!. International Journal of Stroke, 2015, 10, 1167-1167.	2.9	0
587	The Linkage of Global Stroke Organizations. International Journal of Stroke, 2015, 10, 275-275.	2.9	O
588	Women in stroke, and cardiac devices in stroke management. International Journal of Stroke, 2016, 11, 273-273.	2.9	0
589	Penetrating and branch artery disease., 0,, 287-311.		O
590	The crux of stroke management is still prevention. International Journal of Stroke, 2016, 11, 155-155.	2.9	0
591	010â€The melbourne mobile stroke unit substantially improves thrombolysis times and pre-hospital triage. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A5.2-A5.	0.9	O
592	Robert H. Ackerman, MD, MPH, 1935–2018. Stroke, 2019, 50, 779-781.	1.0	0
593	011â€Melbourne mobile stroke unit halves workflow for acute stroke reperfusion therapy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A4.3-A5.	0.9	0
594	International Impact of <i>Stroke</i> . Stroke, 2020, 51, 1036-1039.	1.0	0

#	Article	IF	CITATIONS
595	Posterior Circulation Stroke: Advances in Understanding and Management. Journal of Stroke, 2021, 23, 144-145.	1.4	0
596	Feasibility trial of metformin XR in people with pre-diabetes and stroke (MIPPS)-randomised open blinded endpoint controlled trial. Journal of Clinical Neuroscience, 2021, 86, 103-109.	0.8	0
597	From clinical trial to clinical practice. Neurology India, 2007, 55, 102.	0.2	O
598	Recurrent Stroke Prevention I: Diuretic and Angiotensin-Converting Enzyme Inhibitors (ACEIs) $\hat{a} \in \text{The PROGRESS Trial.}$, 2011, , 143-157.		0
599	Stroke in the coronary care unit., 2011,, 625-632.		O
600	Abstract 14: Predicting Hemorrhagic Transformation in Ischemic Stroke - Very Low Cerebral Blood Volume versus Permeability Analysis. Stroke, 2013, 44, .	1.0	0
601	Recurrent Stroke Prevention: Diuretic and Angiotensin-Converting Enzyme Inhibitors (ACEIs)—The PROGRESS Trial. , 2016, , 215-231.		0
602	Abstract TMP27: How Generalizable are Rehabilitation Trials? The Results of a Large International Rehabilitation Trial (AVERT). Stroke, 2016, 47, .	1.0	0
603	Abstract WP47: Reperfusion Following Ischemic Stroke is Associated with Reduced Brain Edema. Stroke, 2017, 48, .	1.0	0
604	Abstract TP222: Improving the Quality of Acute Stroke Care in regional Australia: The Victorian Stroke Telemedicine Program. Stroke, 2018, 49, .	1.0	0
605	Abstract TP283: Ambulance Service Use and Associations With Hospital Care and 90-day Outcomes for Acute Stroke: The Australian Stroke Clinical Registry (AuSCR). Stroke, 2019, 50, .	1.0	0
606	Abstract WP275: Potential Cost Effectiveness of the Melbourne Mobile Stroke Unit. Stroke, 2020, 51, .	1.0	0
607	Abstract WP33: Reduced Cerebral Blood Flow on Acute Whole Brain CT Perfusion Best Predicts Hemorrhagic Transformation. Stroke, 2013, 44, .	1.0	0
608	Abstract 3: Endovascular Thrombectomy Increases Disability-free Survival, Quality of Life and Life Expectancy After Ischemic Stroke With Reduced Costs. Stroke, 2016, 47, .	1.0	0